All Stories

  1. Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

    Article • Cancer Biology & Therapy, September 2019, Taylor & Francis

    William Figg, Martina Knechel

  2. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters

    Article • Molecular Pharmacology, June 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    William Figg

  3. Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer

    Article • PLoS ONE, February 2019, PLOS

    William Figg

  4. Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.

    Article • Drug Metabolism Letters, November 2018, Bentham Science Publishers

    William Figg

  5. Precision medicine applications in prostate cancer

    Article • Therapeutic Advances in Medical Oncology, January 2018, SAGE Publications

    William Figg

  6. Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients

    Article • Cancer Biology & Therapy, July 2017, Taylor & Francis

    William Figg

  7. Cellular identity crisis: Antiandrogen resistance by lineage plasticity

    Article • Cancer Biology & Therapy, May 2017, Taylor & Francis

    William Figg

  8. Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer

    Article • Cancer Biology & Therapy, February 2017, Taylor & Francis

    William Figg

  9. Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer

    Article • Pharmacogenomics, December 2016, Future Medicine

    William Figg

  10. Pharmacogenomics and histone deacetylase inhibitors

    Article • Pharmacogenomics, November 2016, Future Medicine

    William Figg

  11. Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1α Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells

    Article • Molecular Pharmacology, March 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    William Figg

  12. Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer

    Article • BJU International, February 2013, Wiley

    William Figg

  13. Cabazitaxel

    Article • Cancer Biology & Therapy, December 2010, Taylor & Francis

    William Figg

  14. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer

    Article • Therapeutics and Clinical Risk Management, November 2010, Taylor & Francis

    William Figg

  15. Development of Thalidomide and Its IMiD Derivatives

    Article • January 2008, Springer Science + Business Media

    William Figg

  16. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics

    Article • January 2004, Springer Science + Business Media

    William Figg